Guy Goodwin
| Guy Manning Goodwin | |
|---|---|
| Born | 8 November 1947 |
| Fields | Psychiatry |
| Institutions | University of Oxford, Department of Psychiatry (Medical Sciences Division) |
| Education | B.A. in Animal Physiology, DPhil in Neurophysiology, University of Oxford |
| Known for | Neurobiology of bipolar disorder, neuroscience of mood disorders and brain structure/function imaging |
| Notable awards | Mogens Schou Award for Research, NHS Live Innovation award |
Guy Goodwin is a Senior Research Fellow and until recently was the W.A. Handley Professor of Psychiatry at the University of Oxford (2014). A fellow of the Academy of Medical Sciences, Goodwin has served as principal investigator in many clinical trials for the treatment of bipolar disorder. He has also been on the advisory boards of numerous research councils. He is currently the President of the European College of Neuropsychopharmacology.
Goodwin’s research focuses on the neurobiology of mood disorders, notably bipolar disorder and its treatment. In addition to developing novel treatments for mood disorders, Goodwin is interested in the impact of treatments on both the physiological and psychological levels, using brain imaging techniques to study the effects of treatment on brain structure and function as well as the connection between depression and memory impairment.
Goodwin’s findings on the impact of depression on brain tissue and memory have led to greater interest in neurogenesis when developing antidepressants as well as the role of cognition in the treatment of depression.
Goodwin was the principal investigator of many clinical trials for treatments of bipolar affective disorder, including the BALANCE, CEQUEL, and OXTEXT studies. He serves on the advisory boards of many biopharmaceutical companies including AstraZeneca and Pfizer.
In 2005 Professor Goodwin treated the theatre critic Sheridan Morley for acute depression, using deep brain stimulation.
...
Wikipedia